PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

未开盘 01-12 16:00:00 EST

12.26

-0.08

-0.65%

盘后12.25

-0.01-0.11%

19:18 EST

最高12.41	最低12.17	成交量140.52万
今开12.30	昨收12.34	日振幅1.94%
总市值11.25亿	流通市值10.70亿	总股本9,178万
成交额1,728万	换手率1.61%	流通股本8,727万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":12.26,"timestamp":1768251600000,"preClose":12.34,"halted":0,"volume":1405162,"hourTrading":{"tag":"盘后","latestPrice":12.2466,"preClose":12.26,"latestTime":"19:18 EST","volume":65131,"amount":798508.09,"timestamp":1768263539654},"delay":0,"floatShares":87273400,"shares":91776804,"eps":1.62968,"marketStatus":"未开盘","change":-0.08,"latestTime":"01-12 16:00:00 EST","open":12.3,"high":12.41,"low":12.17,"amount":17275665.84766,"amplitude":0.019449,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.62968,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":12.34,"preHourTrading":{"tag":"盘前","latestPrice":12.22,"preClose":12.34,"latestTime":"09:10 EST","volume":1012,"amount":12355.069804,"timestamp":1768227004429},"postHourTrading":{"tag":"盘后","latestPrice":12.2466,"preClose":12.26,"latestTime":"19:18 EST","volume":65131,"amount":798508.09,"timestamp":1768263539654},"volumeRatio":0.660807,"impliedVol":0.5996,"impliedVolPercentile":0.588},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2603539575","title":"港股异动 | 复宏汉霖(02696)再涨超8% 广谱抗肿瘤PD-L1 ADC HLX43末线食管鳞癌II期数据首次发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2603539575","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603539575?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:12","pubTimestamp":1768270333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港元。消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会上，首度公布了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌的II期概念验证数据，本次发布的数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","HK0000165453.HKD","BK4231","LU1169589451.USD","HK0000320223.HKD","BK4023","BK1161","02696","HK0000320264.USD","ADC","HK0000306701.USD","BK4080","PD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2603357301","title":"PD-1/VEGF双抗交易热潮回归？荣昌生物签下56亿美元授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603357301","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603357301?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:03","pubTimestamp":1768269780,"startTime":"0","endTime":"0","summary":"艾伯维拿下荣昌生物的双抗授权。　　1月12日晚间，中国生物医药企业荣昌生物宣布，与艾伯维达成一笔总金额高达56亿美元的授权合作。　　RC148是荣昌生物研发的一款新型靶向PD-1/VEGF的双特异性抗体药物，其设计旨在激活抗肿瘤免疫反应的同时抑制肿瘤驱动的血管生成。通过同时靶向并抑制PD-1与VEGF通路，有望通过多机制增强免疫系统的抗肿瘤活性。　　值得一提的是，康方生物PD-1/VEGF再度传来新的进展消息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU1064130708.USD","LU1064131003.USD","LU1169590202.USD","LU1969619763.USD","BK1583","688331","BK4023","LU1169589451.USD","09995","LU2148510915.USD","BK1574","BK1161","LU2488822045.USD","LU2328871848.SGD","PD"],"gpt_icon":0},{"id":"2601562331","title":"港股异动 | 复宏汉霖(02696)盘中涨超5% 公司首次公布PD-L1 ADC食管鳞状细胞癌Ⅱ期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2601562331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601562331?lang=zh_cn&edition=full","pubTime":"2026-01-08 11:18","pubTimestamp":1767842338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK4023","BK4080","BK4231","LU1169590202.USD","ADC","BK1161","HK0000165453.HKD","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2601387879","title":"维亚臻生物VSA012注射液启动II期临床 适应症为活动性狼疮肾炎等疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387879","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601387879?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:03","pubTimestamp":1767780180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，维亚臻生物技术（苏州）有限公司的评估VSA012注射液在中国活动性狼疮肾炎患者、原发性IgA肾病患者、C3肾小球病患者和免疫复合物介导的膜增生性肾小球肾炎患者中的有效性和安全性的多中心、开放设计的II期临床研究已启动。这些疾病均属肾脏病症，会损害肾功能，引发蛋白尿、血尿等症状，诊断依赖肾活检及相关检验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107185357a6fe6d42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107185357a6fe6d42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4218","BK4204","PD","PK","LU1169590202.USD","VSA","LU1169589451.USD","BK4181","BK4023"],"gpt_icon":0},{"id":"2601882903","title":"天士力：PD-L1/VEGF双抗的实体瘤适应症IIa期、直肠癌适应症IIb期临床试验正在入组中","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882903","media":"证券日报 ","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601882903?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:36","pubTimestamp":1767620160,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯 1月5日，天士力在互动平台回答投资者提问时表示，根据公司《2025年半年度报告》，PD-L1/VEGF双抗的实体瘤适应症IIa期、直肠癌适应症IIb期临床试验正在入组中；培重组人成纤维细胞生长因子21注射液，临床试验已进入Ib期。后续研发进展公司会根据信息披露相关规定进行公告。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-05/doc-inhfhpmh6572122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-05/doc-inhfhpmh6572122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169589451.USD","BK0196","LU1169590202.USD","BK0028","BK0183","BK4023","BK0188","PD","BK0012","600535","BK0239"],"gpt_icon":0},{"id":"2601020061","title":"科伦博泰生物-B(06990)核心产品TROP2 ADC芦康沙妥珠单抗(SAC-TMT)联合免疫疗法帕博利珠单抗一线治疗PD-L1阳性局部晚期或转移性非小细胞肺癌获NMPA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020061","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601020061?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:01","pubTimestamp":1767571299,"startTime":"0","endTime":"0","summary":"此前，公司公布了芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性NSCLC的3期OptiTROP-Lung05临床试验结果，其在主要终点无进展生存期显示出统计学意义和临床意义的显著改善，并在总生存期方面观察到获益趋势。OptiTROP-Lung05研究是首个免疫联合ADC在一线治疗NSCLC上达到主要终点的3期临床研究。此次在一线治疗PD-L1阳性NSCLC获得突破性疗法认定，将为加速芦康沙妥珠单抗在此适应症审评与上市进程提供助力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4231","LU1169589451.USD","PD","06990","BK4023","LU0196878994.USD","LU1169590202.USD","ADC","BK4080"],"gpt_icon":0},{"id":"2600089095","title":"达伯舒新适应症医保落地 系晚期pMMR子宫内膜癌唯一医保抗PD-(L)1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2600089095","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600089095?lang=zh_cn&edition=full","pubTime":"2026-01-01 15:16","pubTimestamp":1767251765,"startTime":"0","endTime":"0","summary":"中国网财经1月1日讯今日，北京、上海、苏州、郑州等多地医院开出信迪利单抗注射液(达伯舒)新增子宫内膜癌适应症医保处方，标志着该适应症在被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》后正式落地执行医保价格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601013607458241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601013607458241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169590202.USD","PD","LU1169589451.USD","LU2487616109.SGD","LU0053666078.USD","BK4585","BK4588","LU0210528500.USD","BK4023","BK4107","L"],"gpt_icon":0},{"id":"2592795703","title":"【新股IPO】国元国际：瀚思艾泰-B(03378)CD47/PD-1双特异性抗体具备独特性 建议谨慎申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2592795703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592795703?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:55","pubTimestamp":1765940103,"startTime":"0","endTime":"0","summary":"2023 年5月获FDA批准开展 HX009 Ib/II 期治疗 DLBCL 研究。公司的管线有独特的竞争优势，截至2025年12 月 1 日，全球无已获批的 CD47/PD-1 双特异性抗体产品，HX009在该靶点组合中处于唯一性地位。上市后市值在 38.14-43.59 亿港元，但考虑到公司的 CD47/PD-1 双特异性抗体有一定的独特性，如果上市之后，产品有较大的潜力，建议谨慎申购。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK1535","LU1169589451.USD","BK1173","BK4023","03378","PD"],"gpt_icon":1},{"id":"2591164645","title":"康辰药业(603590.SH)：KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591164645?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:05","pubTimestamp":1765800325,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康辰药业(603590.SH)发布公告，近日，公司自主研发的KC1036片(简称“KC1036”)，顺利完成“KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌临床试验(KC1036-COM-01)”首例受试者入组服药。KC1036是公司自主研发的化学药品1类创新药，公司拥有该产品的全球知识产权。KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。KC1036具有较强的VEGFR血管靶向，抑制肿瘤细胞生长;通过抑制AXL，可以改善宿主的抗肿瘤免疫应答，从而避免肿瘤的免疫逃逸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603590","PD","LU1169590202.USD","LU1169589451.USD","BK0239","BK4023"],"gpt_icon":0},{"id":"2590504741","title":"产业新闻 | FDA授予百时美施贵宝PD-1疗法组合优先审评资格；创新帕金森病免疫疗法积极试验结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504741","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504741?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:00","pubTimestamp":1765497601,"startTime":"0","endTime":"0","summary":"FDA授予百时美施贵宝PD-1疗法组合优先审评资格百时美施贵宝今日宣布，美国FDA已受理Opdivo的补充生物制品许可申请，用于与多柔比星、长春花碱和达卡巴嗪联合，治疗既往未接受治疗的III期或IV期经典型霍奇金淋巴瘤成人及儿童患者。FDA授予该申请优先审评资格，并将PDUFA日期确定为2026年4月8日。此次FDA受理及优先审评的决定，主要基于3期SWOG S1826研究的积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1868837136.USD","LU1032466523.USD","LU0114720955.EUR","BK4585","BK4007","LU0321505439.SGD","IE00B2B36J28.USD","LU0868494617.USD","IE0002141913.USD","LU1989771016.USD","LU1868837300.USD","LU2242646821.SGD","LU1670711123.USD","LU2125154935.USD","LU2133065610.SGD","LU1169589451.USD","BMY","LU0321505868.SGD","LU2242652126.USD","BK4534","LU1868836591.USD","LU1670711040.USD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU1868836757.USD","LU0096364046.USD","PD","LU1169590202.USD","BK4581","LU1430594728.SGD","BK4023","BK4532","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1571399168.USD","LU1323610961.USD","LU1670710588.SGD","LU1718418525.SGD","LU0456855351.SGD","IE0009355771.USD","LU0267386448.USD","LU0985481810.HKD","LU1291159041.SGD","BK4588","IE00BJT1NW94.SGD","LU1261432733.SGD","LU1093756325.SGD","LU1585245621.USD","IE00BFXG1179.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2590563981","title":"港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563981","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563981?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:45","pubTimestamp":1765421137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盘中涨超7%，截至发稿，涨5.57%，报81.5港元，成交额3.1亿港元。会上，由荣昌生物自主研发的PD-1/VEGF双特异性抗体RC148单药及联合方案一线或二线治疗非小细胞肺癌的一项Ⅰ/Ⅱ期临床研究数据，以壁报形式正式发布。据悉，今年8月，RC148已获FDA批准在美国开展II期临床试验。获得FDA的IND许可，标志着该药将进入全球临床开发阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","LU1064131003.USD","LU1169589451.USD","LU2148510915.USD","PD","LU1969619763.USD","BK4023","BK1574","BK0239","LU1064130708.USD","LU2488822045.USD","BK1161","LU1169590202.USD","LU2328871848.SGD","BK1583","688331"],"gpt_icon":0},{"id":"2589801094","title":"和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801094","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801094?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:06","pubTimestamp":1765152368,"startTime":"0","endTime":"0","summary":"数据显示，ABSK043与伏美替尼的“靶免联合”方案展现出良好的安全性和耐受性。研究结果显示，ABSK043联合伏美替尼表现出可控的安全性和良好的耐受性。剂量递增阶段的研究结果表明，ABSK043联合伏美替尼不仅安全性可控、耐受性良好，还展现出令人鼓舞的初步抗肿瘤活性。上述积极结果为正在开展的剂量扩展阶段奠定了基础，该阶段将评估ABSK043联合伏美替尼作为一线疗法，用于治疗初治的EGFR突变、PD-L1阳性的NSCLC患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","IE00B543WZ88.USD","LU1169590202.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","02256","LU1169589451.USD","BK1161","PD","LU2476274308.USD","LU2488822045.USD","LU2476274720.SGD","BK1574","LU2778985437.USD","BK4023","09939","BK1515"],"gpt_icon":0},{"id":"2589289437","title":"ADC药物与PD-1/VEGF双抗联用再添案例 科伦博泰与Crescent达成双向授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289437","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589289437?lang=zh_cn&edition=full","pubTime":"2025-12-05 19:52","pubTimestamp":1764935561,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰（HK06990）与CrescentBiopharma,Inc.（一家纳斯达克上市公司，以下简称Crescent）共同宣布，双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物（抗体偶联药物）SKB105在中国以外权利授权Crescent，并预计将获得最高超13亿美元的授权收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584015760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584015760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","PD","LU1169590202.USD","ADC","BK4080","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2589865213","title":"ADC与PD-1红海之外，宝济药业如何找到生物医药的“第二增长曲线”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589865213?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK4080","BK4023","BK4231","PD","LU1169590202.USD","161726","LU1169589451.USD","399441","ADC"],"gpt_icon":1},{"id":"2588709367","title":"复宏汉霖PD-L1 ADC II期结果读出；*ST苏吴进入退市整理期｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709367","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588709367?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:01","pubTimestamp":1764630081,"startTime":"0","endTime":"0","summary":"丨2025年12月2日星期二丨NO.1复宏汉霖PD-L1ADCII期结果读出11月26日，复宏汉霖发布公告表示将在ESMOAsia2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1ADC药物HLX43在宫颈癌领域的II期研究结果。点评：针对PD-L1ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023579600777.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023579600777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","LU1169590202.USD","600200","02696","BK4023","ADC","HK0000165453.HKD","PD","BK0028","BK4231","BK1161","BK0188","BK0060","09939","159938","BK4080","BK1574","LU1169589451.USD","BK0012","BK0239"],"gpt_icon":0},{"id":"1169730844","title":"异动解读 | PagerDuty盘中大跌16.96%，CFO退休计划及下调年度收入预期引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1169730844","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169730844?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:34","pubTimestamp":1764167674,"startTime":"0","endTime":"0","summary":"PagerDuty（股票代码：PD）今日盘中股价大幅下跌16.96%，成为市场关注的焦点。消息面上，公司首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。这一突如其来的高管变动引发了投资者对公司财务管理连续性的担忧，导致股价承压。此外，PagerDuty还下调了其26财年的收入预期，从原先的4.93-4.97亿美元下调至4.9-4.92亿美元。公司表示，这一调整是由于定价和市场过渡的影响。市场普遍认为，这一负面预期进一步加剧了投资者的抛售情绪。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1175428775","title":"异动解读 | PagerDuty盘前大跌5.8%，CFO退休计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1175428775","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175428775?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:14","pubTimestamp":1764148457,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.（股票代码：PD）今日盘前股价大跌5.8%，引发了市场的广泛关注。消息面上，公司首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。这一突如其来的人事变动可能引发了投资者对公司财务管理连续性的担忧，从而导致股价下跌。CFO的离职通常会对公司产生重大影响，尤其是在没有明确继任计划的情况下。投资者可能担心这一变动会影响PagerDuty的财务策略和执行能力。市场将密切关注公司未来的公告，以评估这一人事变动对长期发展的影响。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1188385986","title":"异动解读 | PagerDuty夜盘大跌6.13%，CFO退休计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1188385986","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188385986?lang=zh_cn&edition=full","pubTime":"2025-11-26 12:36","pubTimestamp":1764131803,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.（股票代码：PD）今日夜盘股价大跌6.13%，引发了市场的广泛关注。消息面上，公司首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。这一突如其来的人事变动可能引发了投资者对公司财务管理连续性的担忧，从而导致股价下跌。CFO的离职通常会对公司产生重大影响，尤其是在没有明确继任计划的情况下。投资者可能担心这一变动会影响PagerDuty的财务策略和执行能力。市场将密切关注公司未来的公告，以评估这一人事变动对长期发展的影响。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1138300127","title":"异动解读 | PagerDuty股价盘后大跌7.11%，CFO宣布退休计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1138300127","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138300127?lang=zh_cn&edition=full","pubTime":"2025-11-26 05:32","pubTimestamp":1764106356,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.今日盘后股价大跌7.11%，引发市场关注。据悉，PagerDuty首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。CFO的离职通常会对公司产生重大影响，尤其是在没有明确继任计划的情况下。投资者可能担心这一变动会影响PagerDuty的财务策略和执行能力。市场将密切关注PagerDuty在未来几周内的进一步公告，以评估这一人事变动对公司长期发展的潜在影响。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1107419902","title":"PagerDuty- 11月22日，Owen Howard Wilson 通知其计划在公司任命继任者后退休，担任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1107419902","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107419902?lang=zh_cn&edition=full","pubTime":"2025-11-26 05:13","pubTimestamp":1764105189,"startTime":"0","endTime":"0","summary":"PagerDuty- 11月22日，Owen Howard Wilson 通知其计划在公司任命继任者后退休，担任首席财务官","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169590202.USD","BK4023","LU1169589451.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":-0.0569},{"period":"3month","weight":-0.2245},{"period":"6month","weight":-0.1716},{"period":"1year","weight":-0.3038},{"period":"ytd","weight":-0.0648}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.02996},{"month":2,"riseRate":0.5,"avgChangeRate":-0.032478},{"month":3,"riseRate":0.5,"avgChangeRate":-0.018297},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.049825},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.007313},{"month":6,"riseRate":0.714286,"avgChangeRate":0.021791},{"month":7,"riseRate":0.571429,"avgChangeRate":0.017838},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.000522},{"month":9,"riseRate":0,"avgChangeRate":-0.114196},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.036422},{"month":11,"riseRate":0.571429,"avgChangeRate":0.021164},{"month":12,"riseRate":0.571429,"avgChangeRate":0.042574}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}